Compare Aptiv PLC (APTV) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Bristol-Myers Squibb Co — how do they compare? Aptiv PLC trades at $50.24 (market cap $10.34B), while Bristol-Myers Squibb Co trades at $63.63 (market cap $132.45B). The key difference: Bristol-Myers Squibb Co is far larger — about 12.8× Aptiv PLC's market cap, and Bristol-Myers Squibb Co pays a 3.89% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | BMY | |
|---|---|---|
Market Cap | $10.34B | $132.45B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $65.89 |
52-Week Low | $46.30 | $42.60 |
Enterprise Value | $15.27B | $166.44B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV stock trades at $49.55, up 7.02% in the last session, but remains under bearish technical pressure with support at $48 and resistance at $50. The company reported Q2 2026 EPS of $1.63, beating estimates, but lowered full-year guidance due to weak China demand. Revenue grew 2% year-over-year to $20.4B in 2025, though net margins compressed to 1.07%.
The outlook is mixed: strong analyst buy consensus (63.6%) and a $70.09 price target suggest upside, but technical weakness, margin pressures, and China exposure pose near-term risks. Earnings beats highlight operational strength, but investors face volatility from guidance cuts and competitive headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
